Our Strengths
Our key strengths include the following:
-
Sales growth of RUCONEST®.
-
Proven rare-disease commercialization capabilities.
-
Internal pipeline of product candidates.
-
Transgenic Production Platform Technology.
-
Data exclusivity, know-how and intellectual property.
Our Strategy
Our goal is to be a leading biopharmaceutical company focused on offering treatment options for patients with unmet medical needs, focused on rare diseases.
Our three-pillar strategy for achieving our goal is:
-
Continuing to grow sales of RUCONEST® through further country launches and increasing acute HAE attack treatment market share
-
Expanding indications for rhC1INH and clinical development and commercialization of new recombinant human proteins using our platform technology
-
rhC1INH for additional large unmet indications, such as Acute Kidney Injury, Pre-eclampsia, and COVID-19.
-
Developing more convenient forms of RUCONEST®.
-
Leveraging our transgenic manufacturing technology to develop next-generation protein replacement therapies.
-
-
In-licensing or acquiring drug candidates that are in the late-stages of clinical development and that can potentially leverage our commercial infrastructure
-
Developing leniolisib for the treatment of APDS.
-
Developing or acquiring new programs or companies that can be commercialized using our sales and marketing infrastructure.
-
Taal aanpassen
Wilt u overschakelen naar een andere taal? Klik hier voor de Nederlandse website.